Protocol Ledger

NCT07629440 · Phase III · RECRUITING

A Study to Learn About How a New Pneumococcal Vaccine Works in Infants.

Interventional Phase III clinical trial protocol NCT07629440 sponsored by Pfizer in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-05-29 Enrollment: 3,230 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07629440
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)3,230 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07629440
Protocol FieldVerified Registry Value
NCT IdentifierNCT07629440
Consolidated Lead SponsorPfizer
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment3,230 participants (ESTIMATED)
Registered Start Date2026-05-29
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07629440
Hospital Research SiteLocationSite Profile
Advanced Research Center, Inc.Anaheim, CAOpen Hospital Dossier ->
Stanford Health Care and Stanford Cancer InstituteStanford, CAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI